Cell line · CVCL_1603
Papers81
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 81
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| EIF3I reprograms iron metabolism to promote gastric cancer progression by stabilizing YAP. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRACD loss drives hypoxia-induced immune escape in gastric cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| METTL7A Downregulation Drives SLC1A5-Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Yes-Associated Protein Drives Helicobacter pylori-Induced Metaplastic Changes in Gastric Epithelium. | Cell Mol Gastroenterol Hepatol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Role of NADPH Oxidase 4 in Neutrophil-Mediated Immune Escape in Gastric Cancer. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Salinomycin as a death switch: how gastric cancer cells choose their demise. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering tandem VHHs to target different epitopes to enhance antibody-dependent cell-mediated cytotoxicity. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1603/papers